Evaluation of the sulphapyridine acetylator phenotyping test in healthy subjects and in patients with cardiac and renal diseases.
The acetylator phenotype of 35 healthy, drug-free volunteers and 21 patients with cardiac and/or renal disease has been assessed using oral sulphapyridine. Comparative evaluation of a simplified and a more selective method of sulphapyridine analysis was performed. Thirteen of the patients were also phenotyped by determination of plasma isoniazid half-life. 81% of the patients were slow acetylators, compared with only 51% of the volunteers. When phenotyping healthy, drug-free subjects the analytical procedure, involving a direct estimation of sulphapyridine in urine with the Bratton-Marshall procedure, was satisfactory. On the other hand, in patients receiving concomitant drug therapy the more selective analytical procedure was necessary in order to diminish the risk of methodological interference.
D000107:Acetylation; D000328:Adult; D000368:Aged; D002625:Chemistry, Organic; D005069:Evaluation Studies as Topic; D005260:Female; D006207:Half-Life; D006331:Heart Diseases / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D007538:Isoniazid; D007674:Kidney Diseases / Q000235:genetics / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D055601:Organic Chemistry Phenomena; D010641:Phenotype; D013424:Sulfanilamides; D013427:Sulfapyridine / Q000378:metabolism
D013424:Sulfanilamides; D007538:Isoniazid; D013427:Sulfapyridine